Condensed Statements of Stockholders’ Equity and Comprehensive Income (USD $) In Thousands, except Share data, unless otherwise specified	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated Translation Adjustment [Member]	Total
Balance at Jun. 30, 2011	$ 99,805	$ 740	$ (968)	$ (50,705)	$ 32,556	$ 81,428
Balance (in Shares) at Jun. 30, 2011	181,417,556		(1,311,034)
Comprehensive income
Exchange differences on translation of foreign operations					(3,066)	(3,066)
Net loss				(11,252)		(11,252)
Total Comprehensive income						(14,318)
New shares issued on exercise of options	353	(353)
New shares issued on exercise of options (in Shares)	232,155
Share-based compensation		279				279
Balance at Dec. 31, 2011	100,158	666	(968)	(61,957)	29,490	67,389
Balance (in Shares) at Dec. 31, 2011	181,703,711		(1,311,034)
Balance at Jun. 30, 2012	100,394	668	(1,397)	(69,900)	29,516	59,281
Balance (in Shares) at Jun. 30, 2012	182,350,316		(1,816,178)			182,350,316
Comprehensive income
New shares issued on vesting of options on merger	1,118	(1,118)
New shares issued on vesting of options on merger (in Shares)	4,639,104
Acquisition of Nabi Biopharmaceuticals	(98,521)	233,367	(115,651)			19,195
Acquisition of Nabi Biopharmaceuticals (in Shares)	(153,398,048)		(4,051,183)			0.1249539870
Restricted stock units, net	21	(21)
Restricted stock units, net (in Shares)	214,983
Comprehensive income
Exchange differences on translation of foreign operations					1,001	1,001
Net loss				(2,413)		(2,413)
Total Comprehensive income						(1,412)
New shares issued on exercise of options	410	(410)
New shares issued on exercise of options (in Shares)	413,335
Share-based compensation		1,898				1,898
Balance at Dec. 31, 2012	$ 3,422	$ 234,384	$ (117,048)	$ (72,313)	$ 30,517	$ 78,962
Balance (in Shares) at Dec. 31, 2012	34,219,690		(5,867,361)			34,219,690